US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Kelyniam Global, Inc.

0.1091

0.0000

Volume:- -

Turnover:- -

Market Cap:5.51M

PE:-14.82

High:0.1091

Open:0.1091

Low:0.1091

Close:0.1091

52wk High:0.3000

52wk Low:0.0530

Shares:50.54M

Float Shares:49.41M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0074

EPS(LYR):-0.0074

ROE:-31.64%

ROA:-9.25%

PB:8.89

PE(LYR):-14.82

Loading ...

Overview Company News Filings

Kelyniam Global Q3 revenue falls 12% to $2.19 million

Press Release: Kelyniam Global Announces Q3 2025 Financial Results

Kelyniam Global Renews Licensing Agreement with Finceramica

Kelyniam Global Renews Licensing Agreement With Finceramica, Unlocking Access to Valuable Pipeline Products

THOMSON REUTERS

Kelyniam Global, Inc. Receives FDA Clearance for Innovative Fusion™ Bcp-Peek Implant

THOMSON REUTERS

Kelyniam Global Inc. to Present at Life Sciences Virtual Investor Forum

Kelyniam Global Inc. Uplists to OTCID Market Tier, Enhancing Transparency and Investor Confidence

Kelyniam Global Q2 2025 Results: Revenue Down 20.2%, Operating Loss of $59,869

Kelyniam Global Announces Q2 2025 Financial Results

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/KLYG/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KLYG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLYG\",,,,,undefined,":{"symbol":"KLYG","market":"US","secType":"STK","nameCN":"Kelyniam Global, Inc.","latestPrice":0.109055,"timestamp":1772485200000,"preClose":0.109055,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":49410800,"shares":50543400,"eps":-0.007359,"marketStatus":"Closed","change":0,"latestTime":"03-02 16:00:00 EST Delay","open":0.109055,"high":0.109055,"low":0.109055,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.007359,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1772528400000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"PINK","adjPreClose":0.109055,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLYG\",,,,,undefined,":{"symbol":"KLYG","floatShares":49410800,"roa":"-9.25%","roe":"-31.64%","lyrEps":-0.007359,"shares":50543400,"dividePrice":0,"high":0.109055,"amplitude":0,"preClose":0.109055,"low":0.109055,"week52Low":0.053,"pbRate":"8.89","psRate":"2.06","week52High":0.3,"institutionHeld":0,"latestPrice":0.109055,"eps":-0.007359,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.007359,"open":0.109055,"prevYearClose":0.1165,"prevWeekClose":0.1091,"prevMonthClose":0.1091,"prevQuarterClose":0.1165,"fiveDayClose":0.1134,"twentyDayClose":0.13,"sixtyDayClose":0.1121},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KLYG\",params:#limit:5,,,undefined,":[{"market":"US","date":"2021-05-18","symbol":"KLYG","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1621310400000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2021-04-02","symbol":"KLYG","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1617336000000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2020-11-16","symbol":"KLYG","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1605502800000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2020-05-18","symbol":"KLYG","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1589774400000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2019-12-13","symbol":"KLYG","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1576213200000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KLYG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KLYG\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KLYG\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2582807634","title":"Kelyniam Global Q3 revenue falls 12% to $2.19 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582807634","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582807634?lang=en_us&edition=fundamental","pubTime":"2025-11-11 04:56","pubTimestamp":1762808189,"startTime":"0","endTime":"0","summary":"Kelyniam Global Inc. reported year-to-date revenue of $2.2 million for Q3 2025, a decrease of 12.3% compared to $2.5 million in Q3 2024. Gross profit was $1.7 million, down 13.3% from $2.0 million in the prior year period. The company reported an operating loss of $162,400, compared to operating income of $273,200 in Q3 2024. Key business developments included FDA 510 clearance for the Vestakeep resorbable bi-calcium phosphate implant and ongoing Value Analytics review at six major U.S. hospitals, potentially adding over $500,000 in annual recurring revenue. Kelyniam also uplisted to OTCID status on the OTC Markets Group platform.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kelyniam Global Inc. published the original content used to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL37KqdW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLYG"],"gpt_icon":0},{"id":"2582076378","title":"Press Release: Kelyniam Global Announces Q3 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2582076378","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582076378?lang=en_us&edition=fundamental","pubTime":"2025-11-11 04:56","pubTimestamp":1762808160,"startTime":"0","endTime":"0","summary":"CANTON, Conn., Nov. 10, 2025 /PRNewswire/ -- Kelyniam Global, Inc. , a leader in custom cranial and craniofacial implants, today reported financial results for the third quarter ended September 30, 2025.-- Year-to-date revenue of $2,186,491, compared to $2,492,607, a decrease of. -- Gross profit of $1,695,496, compared to $1,956,714, a decrease of 13.3%,primarily due to the revenue headwinds offset by stable material costs.reflecting increased investments in sales support and regulatory costs. \"Sales have faced headwinds this year from a slow distributor ramp-up and temporary market share shifts, but through Q3, we're steadily catching up to 2024 levels and building a stronger foundation for sustainable growth,\" said Ross Bjella, CEO of Kelyniam Global. \"The cranial implant sector remains robust, with competitors with overall market projections showing expansion from $1.43 billion in 2024 to over $1.5 billion in 2025. We're capitalizing on this by aggressively adding distributors in un","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLYG","BK4022","R","BK4232"],"gpt_icon":0},{"id":"2581704201","title":"Kelyniam Global Renews Licensing Agreement with Finceramica","url":"https://stock-news.laohu8.com/highlight/detail?id=2581704201","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581704201?lang=en_us&edition=fundamental","pubTime":"2025-11-07 08:09","pubTimestamp":1762474186,"startTime":"0","endTime":"0","summary":"Kelyniam Global Inc. has announced the renewal of its licensing agreement with Finceramica Faenza S.p.A., an Italian biomaterials company. The three-year extension grants Kelyniam expanded access to Finceramica's product portfolio, including SINTlife, a fully resorbable synthetic graft, and Surgery V-Connect, a Smart Augmented Reality System. The agreement is expected to strengthen Kelyniam's position in the U.S. market and enable entry into new markets in bone regeneration and orthopedic applications. SINTlife is anticipated to receive FDA clearance within two years.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kelyniam Global Inc. published the original content used to generate this news brief via GlobeNewswire  on November 07, 202","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL184vjF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2210149790.SGD","BK4585","LU2210150020.SGD","LU0314104364.USD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","KLYG","NDAQ","BK4112","LU2095319765.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2581420490","title":"Kelyniam Global Renews Licensing Agreement With Finceramica, Unlocking Access to Valuable Pipeline Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2581420490","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581420490?lang=en_us&edition=fundamental","pubTime":"2025-11-07 08:09","pubTimestamp":1762474177,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nTUATYWCY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLYG"],"gpt_icon":0},{"id":"2568409606","title":"Kelyniam Global, Inc. Receives FDA Clearance for Innovative Fusion™ Bcp-Peek Implant","url":"https://stock-news.laohu8.com/highlight/detail?id=2568409606","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568409606?lang=en_us&edition=fundamental","pubTime":"2025-09-18 23:23","pubTimestamp":1758209000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250918:nTUA8R3B98:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLYG"],"gpt_icon":0},{"id":"2567167720","title":"Kelyniam Global Inc. to Present at Life Sciences Virtual Investor Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2567167720","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567167720?lang=en_us&edition=fundamental","pubTime":"2025-09-15 12:01","pubTimestamp":1757908874,"startTime":"0","endTime":"0","summary":"Kelyniam Global Inc. is set to present at the Life Sciences Virtual Investor Forum on September 18th, 2025. The company, known for its custom cranial implants, will discuss its sales momentum and product line enhancements, including the CustomizedBone implant licensed from Finceramica Spa and the OsteoStrip and Osteoplug product lines from Osteopore. This online event will be interactive, allowing investors to ask questions in real-time.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kelyniam Global Inc. published the original content used to generate this news brief via PR Newswire  on September 15, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nNDL27xyjm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7126","OSX.AU","KLYG"],"gpt_icon":0},{"id":"2565572968","title":"Kelyniam Global Inc. Uplists to OTCID Market Tier, Enhancing Transparency and Investor Confidence","url":"https://stock-news.laohu8.com/highlight/detail?id=2565572968","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565572968?lang=en_us&edition=fundamental","pubTime":"2025-09-08 12:01","pubTimestamp":1757304080,"startTime":"0","endTime":"0","summary":"Kelyniam Global, Inc., a leading manufacturer of custom cranial and craniofacial implants, has announced the elevation of its share trading platform to the OTCID status on the OTC Markets Group platform, effective September 8, 2025. This upgrade signifies the company's dedication to transparency and compliance, offering investors improved access to current financial information and market data. The OTCID status is a distinction achieved by only a select group of OTC companies, requiring regular financial reporting and adherence to strict compliance criteria. This move is expected to attract a broader investor base and support Kelyniam's long-term growth as it continues to innovate in the custom cranial implant sector.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nNDLccN2s2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTCM","BK4112","KLYG"],"gpt_icon":0},{"id":"2558669730","title":"Kelyniam Global Q2 2025 Results: Revenue Down 20.2%, Operating Loss of $59,869","url":"https://stock-news.laohu8.com/highlight/detail?id=2558669730","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558669730?lang=en_us&edition=fundamental","pubTime":"2025-08-11 23:16","pubTimestamp":1754925410,"startTime":"0","endTime":"0","summary":"Kelyniam Global Inc., a leading manufacturer of custom cranial and craniofacial implants, reported its financial results for the second quarter ending June 30, 2025. The company experienced a 20.2% decrease in total revenue, amounting to $1.364 million compared to $1.709 million in the same period in 2024. The gross margin also declined by 18.1%, reaching $1.091 million from $1.331 million the previous year. Kelyniam reported an operating loss of $59,869, a significant shift from an operating profit of $172,093 in Q2 2024. CEO Ross Bjella highlighted improvements over Q1 2025 results, attributing the gains to focused sales execution and efforts to capitalize on available opportunities in the cranial implant market. Despite the decrease in revenue compared to the previous year, Kelyniam saw increased sales in the latter part of Q2, driven by a strategic focus on sales activities leading into the trauma season. The company's annual shareholder meeting was held on June 23rd, with all offi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nNDL6CQQVk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLYG"],"gpt_icon":0},{"id":"2558669736","title":"Kelyniam Global Announces Q2 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2558669736","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558669736?lang=en_us&edition=fundamental","pubTime":"2025-08-11 23:16","pubTimestamp":1754925390,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nTUA7J6BFQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLYG"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":9,"code":"91000000","status":"200"}]}}